Cargando…
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116235/ https://www.ncbi.nlm.nih.gov/pubmed/33712868 http://dx.doi.org/10.1007/s00277-021-04490-3 |
| _version_ | 1783691350476062720 |
|---|---|
| author | Shoumariyeh, Khalid Jung, Johannes Rassner, Michael Dold, Sandra Maria Riebl, Veronika Pantic, Milena Herget, Georg Marks, Reinhard Lübbert, Michael Wäsch, Ralph Engelhardt, Monika |
| author_facet | Shoumariyeh, Khalid Jung, Johannes Rassner, Michael Dold, Sandra Maria Riebl, Veronika Pantic, Milena Herget, Georg Marks, Reinhard Lübbert, Michael Wäsch, Ralph Engelhardt, Monika |
| author_sort | Shoumariyeh, Khalid |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8116235 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81162352021-05-13 Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab Shoumariyeh, Khalid Jung, Johannes Rassner, Michael Dold, Sandra Maria Riebl, Veronika Pantic, Milena Herget, Georg Marks, Reinhard Lübbert, Michael Wäsch, Ralph Engelhardt, Monika Ann Hematol Letter to the Editor Springer Berlin Heidelberg 2021-03-13 2021 /pmc/articles/PMC8116235/ /pubmed/33712868 http://dx.doi.org/10.1007/s00277-021-04490-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter to the Editor Shoumariyeh, Khalid Jung, Johannes Rassner, Michael Dold, Sandra Maria Riebl, Veronika Pantic, Milena Herget, Georg Marks, Reinhard Lübbert, Michael Wäsch, Ralph Engelhardt, Monika Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab |
| title | Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab |
| title_full | Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab |
| title_fullStr | Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab |
| title_full_unstemmed | Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab |
| title_short | Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab |
| title_sort | treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116235/ https://www.ncbi.nlm.nih.gov/pubmed/33712868 http://dx.doi.org/10.1007/s00277-021-04490-3 |
| work_keys_str_mv | AT shoumariyehkhalid treatmentoftherapyrelatedacutemyeloidleukemiaandunderlyingmultiplemyelomawithdecitabinevenetoclaxanddaratumumab AT jungjohannes treatmentoftherapyrelatedacutemyeloidleukemiaandunderlyingmultiplemyelomawithdecitabinevenetoclaxanddaratumumab AT rassnermichael treatmentoftherapyrelatedacutemyeloidleukemiaandunderlyingmultiplemyelomawithdecitabinevenetoclaxanddaratumumab AT doldsandramaria treatmentoftherapyrelatedacutemyeloidleukemiaandunderlyingmultiplemyelomawithdecitabinevenetoclaxanddaratumumab AT rieblveronika treatmentoftherapyrelatedacutemyeloidleukemiaandunderlyingmultiplemyelomawithdecitabinevenetoclaxanddaratumumab AT panticmilena treatmentoftherapyrelatedacutemyeloidleukemiaandunderlyingmultiplemyelomawithdecitabinevenetoclaxanddaratumumab AT hergetgeorg treatmentoftherapyrelatedacutemyeloidleukemiaandunderlyingmultiplemyelomawithdecitabinevenetoclaxanddaratumumab AT marksreinhard treatmentoftherapyrelatedacutemyeloidleukemiaandunderlyingmultiplemyelomawithdecitabinevenetoclaxanddaratumumab AT lubbertmichael treatmentoftherapyrelatedacutemyeloidleukemiaandunderlyingmultiplemyelomawithdecitabinevenetoclaxanddaratumumab AT waschralph treatmentoftherapyrelatedacutemyeloidleukemiaandunderlyingmultiplemyelomawithdecitabinevenetoclaxanddaratumumab AT engelhardtmonika treatmentoftherapyrelatedacutemyeloidleukemiaandunderlyingmultiplemyelomawithdecitabinevenetoclaxanddaratumumab |